The American Association for the Study of Liver Diseases (AASLD) will be holding its annual meeting soon, and while clinical data remains a key focus, the current and future economic impact of HCV therapies will be a hot topic. What lessons have been learned? What surprises are still in store? Read more here. (Source: Duncan Emerton, FirstWord Pharma, 10/14/14).
You are here: / / Clinical Data & Economic Impact Both Hot Topics In Upcoming Meeting On Liver Diseases